A novel, sensitive colorimetric test is described for quantification of the initial number of hepatitis B virus (HBV) genomes amplified in PCR. The viral genomes are amplified together with a synthetic internal standard (IS) to correct for the variability of the efficiency factor. One of the two primers is biotinylated, and the amplified mixtures of HBV and IS DNAs are bound to streptavidincoated microtiter plates for quantitative detection. The ratio of HBV to IS DNA is determined for each sample by hybridization with DNP-containing probes and immunoenzymatic detection. The colorimetric detection is quantitative, rapid, and accurate with a dynamic range from -1 0 8 to >1011 DNA molecules. The initial number of HBV genomes in a clinical sample is interpreted from the signal ratio HBV/IS by using a standard curve, obtained from coampliflcation of known quantities of synthetic HBV templates with IS. The assay quantified 15 viral genomes from 10 i~1 of serum, and its dynamic range was up to five orders of magnitude. After the amplification step, the assay takes ~2 hr, and the method is applicable to automation. T h e in vitro DNA amplification methods are restricted primarily to qualitative analyses, including the "semiquantitative PCR assays. ''(~ There would be need for validated quantitative assays, especially if they were simple enough for routine diagnostic use. We describe here a practical, rapid, and sensitive nonradioactive method for quantification of the initial n u m b e r of hepatitis B virus (HBV) templates from clinical samples. The method is principally applicable to any DNA.
T h e in vitro DNA amplification methods are restricted primarily to qualitative analyses, including the "semiquantitative PCR assays. ''(~ There would be need for validated quantitative assays, especially if they were simple enough for routine diagnostic use. We describe here a practical, rapid, and sensitive nonradioactive method for quantification of the initial n u m b e r of hepatitis B virus (HBV) templates from clinical samples. The method is principally applicable to any DNA.
In PCR the amount of amplified material is N = N O (1 + ef/0 n, where N O is the initial amount of template, eff is the efficiency, and n is the n u m b e r of cycles. The efficiency of amplification varies from sample to sample and also decreases during cycling. The estimation of the initial quantity of template has been considered difficult because the efficiency factor may be decreased, especially in clinical samples, depending on their quality. Some PCR inhibitors from serum may not be removed completely, and reagents used in pretreatment can be inhibitory. False-negative results may occur without proper standardization. Moreover, the reproducibility of releasing the DNA from the clinical specimen is an important factor affecting the resuit. In the present test, quantification is based on coamplification with an internal standard, which has been applied to eliminate sample-dependent variation in amplification efficiency. ~2--8~ We have described earlier the principle of coamplification in the form a prototype test. (9) Qualitative PCR for HBV DNA has been described frequently, ~176 and the sensitivity of PCR tests has been shown to be at least as good as that of infectivity testings with chimpanzees. (14~ A quantitative PCR assay, capable of monitoring HBV DNA levels at higher sensitivity than present tests, would be required for assessing the efficacy of antiviral therapy. ~12'1s-~7~ A sensitive and quantitative test would also be useful in assessing potential infectivity of problematic cases of donated blood units (~8~ and for assessing whether asymptomatic chronic carriers are contagious.
MATERIALS AND METHODS

DNA Standards, Respective Primers, and Probes
The HBV DNA standard template was synthesized using an Applied Biosystems 381 A Synthesizer. It contained the 104-bp long sequence 1864--1967 from the pre-C and C gene region of HBV genome of subtype ayw. (19~ The synthetic internal standard (IS) DNA was a m u t a n t version of the former, in that the 21-mer internal sequence was replaced by an unrelated sequence. The molecular concentrations of the purified DNAs were determined by spectrophotometry. The primers used were 5'-biotin-GTT CAI GCC TCC AAG CTG TG and 5'-TCA GAA GGC AAA AAI GAG AGT AAC T (I is inosine). These primers were amplifying DNA from the C and pre-C region of the HBV genome (19~ and were obtained from MedProbe A.S. (Oslo, Norway).
In the reference amplification system 2, longer and n o n h o m o l o g o u s competing DNAs were amplified. (9~ The HBV and IS sequences in this system were amplified with c o m m o n primers and were recognized by the probes used in the test. The standard plasmid DNAs were linearized. The primers for the reference amplification system were 5'-B2_4-TTC AAG CCT CCA AGC TGT GCC T (which is overlapping with the biotinylated primer above), and 5'-GTT AGC GGC GCA GCG TCT. (2~ Here, B was a biotinylated C added to the oligonucleotide in an Applied Biosystems A 381 synthesizer using the respective phosphoramidite reagent (M. BengtstrOm, L. Paulin, and B. Sproat, unpubl.).
The detection probe for HBV DNA (5'-CTT TAT AAG GAT CAA TGT CCA TGC) was modified with a dinitrophenyl (DNP) group at the 5' and 3' ends. Also a probe with three DNP groups at the 5' end was used (British Biotechnology, Abingdon, Oxon, UK). The detection probe for IS DNA was similarly labeled. For the quantitative PCR, serum was pretrated by precipitation with polyethylene glycol followed by lysis with NaOH, neutralization, boiling, and centrifugation. An aliquot of the supernatant corresponding to 10-40 p.l of original serum was subjected to amplification by PCR (M. Uusi-Oukari, A. K~ih~ir~i-Uppg~rd, M. Ranki, and P. Lehtovaara, unpubl.)
Clinical Samples
Amplification in Competitive PCR
In addition to HBV DNA, the PCR reaction contained 50 mM Tris-HC1 (pH 8. of primer annealing at 55~ and 1 m i n of primer extension at 72~ except that in the first cycle the denaturation step at 96~ was extended to 6 m i n and the last extension step to 11 rain.
Detection on Microtiter Plates
Each sample was to be hybridized with two different probes (HBV and IS specific, respectively); therefore, 50-~1 aliquots from each PCR sample, first diluted 1 : 4 , were pipetted to microtiter plate wells coated with streptavidin (see Fig. 1 ; HepB sensitive test kit, Sangtec Medical, Bromma, Sweden). Two parallel hybridizations were usually performed. The plate was shaken for 15 m i n at room temperature in a plate shaker. Fifty microliters of 100 mM NaOH and 300 mM NaC1 were added to the wells and, after shaking for 1 rain, the plates were washed three times with 25 mM Tris-HC1 (pH 7.5), 125 mM NaC1, 2 mM MgC12, and 0.3% Tween in a microtiter plate washer. The HBV-or IS-specific DNP probe was added at a concentration of 10 lz molecules per well, and hybridization oc- The plate was washed six times and anti-DNP-alkaline phosphatase conjugate was added [50 i~l of 25 mM HEPES (pH 7.5), 125 mM NaC1, 2 mM MgC1 z, 1% BSA, and 0.3% Tween]. After the plate was shaken at room temperature for 15 min, it was washed six times, and the substrate p-nitrophenyl phosphate (pNPP) was added as 4 mg/ml of solution in standard diethanolamine-MgC12 buffer in a volume of 100 i~l. The reaction was allowed to proceed at room temperature with shaking, and the plate was read spectrophotometrically at 405 nm (Multiscan Plus plate reader, Labsystems, Helsinki, Finland) after suitable time intervals (e.g., 4, 10, 30 min).
RESULTS
Outline of the Assay
The substance of the assay is illustrated in Figure 1 . The clinical sample is pretreated to release the viral genome quantitatively, and an aliquot corresponding to 10 ~l (up to 50 ~l) of serum is subjected to PCR amplification, together with 103 molecules of a synthetic (IS). The IS sequence is identical to the amplified 104-mer sequence of the HBV genome except that it contains an internal 21-met replacement. Coamplification is continued for 30 cycles.
The amplified HBV and IS DNA, both of which are biotinylated at one 5' end, are quantified by binding to streptavidin-coated microtiter plates, removing the nonbiotinylated strands, and hybridizing with an HBV-specific and an IS-specific probe, respectively. The hybridized DNP label is quantified in an immunoenzymatic reaction, and the ratio of the HBV-and IS-specific signals is determined. The initial quantity of the HBV genome is interpreted from a standard curve.
The Standard Curve
To obtain the standard curve (Fig. 2) , known numbers of molecules of the synthetic HBV standard template (usually 102-106 molecules) were coamplified with 103 molecules of IS. The signal ratios of HBV/IS were determined and plotted against the initial n u m b e r of HBV DNA molecules in a logarithmic scale. Molecules of H B V DNA standard before amplification
Competitive amplification of HBV DNA and IS DNA: the standard curve for the assay with 104-bp long synthetic templates with 80% homology (O) and from the reference amplification system 2 (1). The initial number of IS DNA molecules was always 103. The two standard curves were each a mean of three to four individual experiments. The third linear curve is theoretical, assuming an identical amplification efficiency for HBV and IS DNA at all combinations.
plified with an identical amplification efficiency, and the initial ratio of the templates would not affect the efficiency, it would be possible to calculate the results directly (see theoretical curve, Fig. 2 ). The ratio of HBV/IS after amplification would be multiplied by the known initial quantity of IS, as the ratio would remain constant. However, the slope of the experimental curve in Figure  2 , obtained by coamplifying the synthetic 104-bp standards, was less steep than that of the theoretical slope. Also dilution series of the authentic viral genome showed results similar to those from the synthetic template. Thus, the initial ratio of the two templates had some effect on the amplification efficiency, which had to be corrected by using a standard curve. The experimental standard curve established the correlation between the signal ratio HBV/IS and the initial quantity of HBV DNA over four to five orders of magnitude.
The synthetic 104-bp-long HBV and IS DNA standards were designed to have a high degree of homology (80% of the sequences were identical), because it has been generally assumed that the sequence of a competing IS ought to be as homologous as possible to the target DNA. (4'22) We also studied the performance of the assay with an IS template totally unrelated to the HBV template except at the c o m m o n primer regions (amplification system 2) (Fig. 2) . Interestingly, the competition a m o n g highly homologous DNAs and the competition of unrelated longer sequences gave almost indistinguishable results for the standard curves. The only minor differences were that the linear range was reproducibly larger and the efficiency was better with the homologous standards, which were amplified as shorter fragments. Both amplification systems can, in principle, be used in the quantitative test.
Validation of Quantitative Nonradioactive Detection
The amplified biotinylated products were quantitatively bound to a streptavidin-coated microtiter plate well in 15 min with shaking. The b o u n d DNA was made single stranded with brief alkali treatment before hybridization with single-stranded, DNP-labeled oligonucleotide probe. Quantitative hybridization occurred rapidly, within 5-15 min at room temperature, depending on the probe concentration (data not shown).
The DNP-labeled hybrids were detected by an anti-DNP-alkaline phosphatase conjugate, which produced a spectrophotometrically measurable product from the pNPP substrate. Because the kinetics of this reaction was linear over 4 hr (Fig. 3) , the dynamic range for the colorimetric detection could be expanded by taking advantage
PCR Methods and Applications 171
Cold E n z y m e reaction time (min) FIGURE 3 Linearity of the enzyme reaction in colorimetric quantification of biotinylated HBV DNA on microtiter plates. Various amounts of purified PCR product (from amplification system 2) were bound to the plate and quantified. Hybridization was with DNP-labeled oligonucleotide containing an average of 1.5 DNP groups, and the hybrids were detected with anti-DNP-alkaline phosphatase conjugate. Formation of the reaction product from the pNPP substrate was followed at 405 nm at time intervals. The results were a mean of four parallel determinations.
of repeated m e a s u r e m e n t s and extrapolation, for example, routinely m e a s u r i n g the e n z y m e reaction after 4, 10, and 30 min. It was possible to cover m o r e t h a n three orders of m a g n i t u d e in this colorimetric m e a s u r e m e n t : The lowest detectable a m o u n t was -1 0 8 DNA m o l e c u l e s (in a 3 0 -m i n reaction time) and the highest was >1011 molecules (4 m i n ) as s h o w n in Figure 4 . A cutoff value d e f i n e d as a signal-to-noise ratio of 2, corres p o n d e d to -2 x 10 s molecules of DNA, and d e f i n e d as the m e a n of blank values + 3 S.D. to --10 s molecules (Fig. 4) . The dynamic range of the colorimetric quantification of biotinylated HBV DNA. The amplified 104-bp-long biotinylated HBV DNA was purified, and quantified spectrophotometrically, and different amounts were bound to the microtiter plate in a volume of 50 i~l. The detection probe contained three successive DNP groups at the 5' end. The cutoff limits 1 and 2 denote the mean of blank readings plus three standard deviations and a signal-to-noise ratio of 2, respectively. Figure 3 w i t h four parallel samples at each point.
The d e t e c t i o n assay was q u a n t i t a t i v e and h i g h l y reproducible. The coefficient of variation (CV) for t h e d e t e c t i o n step was 3.2%, m e a s u r e d in the e x p e r i m e n t s h o w n in
Accuracy of Quantification of HBV DNA from Serum Samples
An i m p o r t a n t prerequisite for a quantitative PCR assay for HBV DNA is that t h e s p e c i m e n p r e t r e a t m e n t results in q u a ntitative a n d r e p r o d u c i b l e DNA yields from different sera, irrespective of t h e virus c o n c e n t r a t i o n or t h e quality of t h e sample. We have d e v e l o p e d a pretreatm e n t m e t h o d that gives q u a n t i t a t i v e a n d reproducible yields for viral DNA (M. Uusi-Oukari, A. K~ih~ir~i-Uppg~rd, M. Ranki, a n d P. Lehtovaara, in prep.).
A reference test for q u a n t i f i c a t i o n was used to d e m o n s t r a t e the reliability of the quantitative PCR test. The AffiProbe HepB test (23) aThe expected number of molecules is based on the AffiProbe results. The samples (except AffiProbe-negative sample 3) were diluted 1:100 with negative control serum before quantification with the PCR test. bThe undiluted sample 15 was pretreated with the method used for the PCR test before AffiProbe detection. After pretreatment, it was diluted with buffer and quantified with the PCR test using the reference amplification system.
Dynamic Range and Reproducibility of Quantification from Serum Samples
Clinical samples were serially diluted A with normal h u m a n serum to assess the dependence of the quantitative result on the a m o u n t of virus in serum and to determine the sensitivity and dynamic range for quantification. As shown by an example in Figure 5A , the quantitative results were correctly dependent on virus concentration over up to five orders of magnitude. On the basis of the titer determined by the AffiProbe HepB test, (z3) the dynamic range shown in Figure 5A was from 15 to 1.5x10 6 viral gen o m e templates in 10 lal of serum. Other clinical samples also gave similar curves. Thus, it can be concluded that the test is quantitative in a range of five orders of magnitudes.
The most sensitive range of the m e t h o d was studied in more detail using the Eurohep reference specimen at our disposal. Its HBV DNA content had been determined to be 10 9 Eurohep U/ml, with 1 Eurohep unit being 1-5 HBV DNA molecules. (2~) By our quantitative AffiProbe HepB test, (z3) its HBV DNA titer was 109 molecules/ml. The specimen was serially diluted with HBV-negative serum and these dilutions were subjected to the quantitative PCR test. Figure 5B shows that the test was capable of quantifying 16 viral genomes/10 I~1 of serum. The titer of the undiluted Eurohep sample, determined from the dilution ( 1 : 2 x 106) by using the standard curve was 1.4x109/ml (Fig. 5B) .
The reproducibility of the quantitative PCR test was good, taking into account the dynamic range. W h e n four clinical samples with titers 104-106 HBW ml were pretreated and quantified four times, the titers obtained had a CV percent of -2 0 % and maximally threefold differences could be detected (data n o t shown). Variation caused by the amplification reaction gave rise to no more than twofold differences in the titer, showing that a single amplification reaction from each sample was sufficient. The reproducibility of the test in the most sensitive region of the assay is shown in Table 2 , where clinical samples containing very low quantities of virus (2.8 x103-9 x104 HBWml) were analyzed. Control serum gave extremely low signals irrespective of sample quantity, whereas the signals from viral samples responded to the quantity applied to PCR. Thus, volumes corresponding to at least 40 ixl of serum could be subjected to PCR to increase the sensitivity and reliability of the assay. The quantitative results obtained were highly reproducible even at the lowest end of the d y n a m i c range.
DISCUSSION
The PCR test enables accurate quantifi- The results also indicated that the test is not sensitive to strain differences (the viral strains were not known, but the sera were obtained from patients who were from Asia, Africa, and Western and Eastern Europe). The quantitative analysis of competitive PCR reactions typically has been tedious so far, with separation of the two products by electrophoretic techniques or HPLC. (1'6'8'z~ In most cases, quantification has been performed with isotopic label. Moreover, the competitive amplification is tedious w h e n multiple PCR reactions are performed to titrate one sample with IS. (z'~8"zz) In the present test, a single amplification is sufficient; therefore, several samples can be analyzed in one experiment. No tedious separation is necessary to quantify the amplified products. The nonradioactive detection system permits adequate and sensitive quantification, whereas the nonisotopic detection systems described previously for HBV DNA were used for qualitative assays only. (24'2s) The IS template of the present assay was synthetic, 104-bp long, and 80% identical to the HBV DNA amplified. The assay was also completely functional, however, with a n o n h o m o l o g o u s IS (amplification system 2), indicating that there are several choices for a suitable IS DNA.
W h e n different quantitative tests are compared, it is of interest to analyze their standardization and evaluate how close the results are to the absolute titers. The Eurohep reference plasma (1 x 109 to 5x109 HBV DNA/ml) gave the result 1.4x109 HBV DNA/ml in the PCR test and l x 1 0 9 HBV DNA/ml in AffiProbe HepB. The other clinical specimens that could be tested by both assays showed on the average of 2.1-fold (S.D. 1.2) higher titers in the PCR assay as compared with the AffiProbe HepB. In the PCR test, during the very first cycles, mispriming was more possible theoretically from the 3.2-kb genomic template than from the 104-bp-long HBV or IS templates. This could slightly overestimate the sample in the PCR test. The reference test AffiProbe, on the other hand, has a slightly underestimating standardization (vector sequences present both in standards and nick-translated probes). The conclusion is that all of the results were in good agreement and thus reliably quantified HBV DNA.
As in all PCR tests, c o n t a m i n a t i o n of unamplified samples with amplified material has to be prevented by standard precautions. The limitations caused by strain differences have been minimized by amplifying a well-conserved region and using the universal base inosine in primers and probes. The AffiProbe test with long probes and no amplification is not sensitive to strain differences, and n o n e of the samples tested so far with the two tests have shown clearly test-dep e n d e n t results.
With each step optimized and validated, the test offers a c o n v e n i e n t new possibility for accurate m o n i t o r i n g of HBV DNA levels in serum and plasma samples in a large dynamic range. The present sensitivity is likely to be sufficient for quantitative m o n i t o r i n g of the virus in most clinical applications.
